Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNK01 + cetuximab
- Development stage
- Preclinical
- Lead developer
- NKGen Biotech, Inc.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
SNK01 + cetuximab is a combination investigational therapy consisting of SNK01, an autologous non-genetically modified enhanced natural killer (NK) cell product, and cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody. SNK01 is designed to augment the cytotoxicity and activating receptor expression of a patient’s own NK cells, potentially improving antitumor activity across both solid and hematologic malignancies. Cetuximab blocks EGFR signaling, inhibiting tumor growth and promoting antibody-dependent cell-mediated cytotoxicity partly via NK cell activation. The combination is under exploration to leverage synergistic immune-mediated antitumor effects, primarily in oncology indications.
- Brand names
- Erbitux
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on SNK01 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNK01 + cetuximab.